---

---

Colorado - Prescription Drug Advisory Board

Statute:
https://leg.colorado.gov/sites/default/files/2021a_175_signed.pdf

PDAB (includes public meeting notices):
https://doi.colorado.gov/insurance-products/health-insurance/prescription-drug-affordability-review-board

Public Comment:

• 02/03/25 - Colorado General Assembly - Joint Budget Committee
  Re: Funding for the Prescription Drug Affordability Board
• 12/30/24 - Colorado Department of Regulatory Agencies - Executive Director’s Office
  Re: Request for Cost-Benefit Analysis; 3CCR 702-9
• 12/19/24 - Colorado Division of Insurance
  Re: Request for Regulatory Analysis; 3CCR 702-9
• 11/26/24 - Colorado Prescription Drug Affordability Board Meeting
  Re: Comments Concerning Ongoing Rulemaking
• 10/15/24 - Colorado Prescription Drug Affordability Board Meeting
  Re: Affordability Review Rulemaking and Ongoing Policy Activities
• 09/04/24 - Colorado Prescription Drug Affordability Board Meeting
  Re: Ongoing Affordability Review and UPL Development
• 02/23/24 - Colorado Prescription Drug Affordability Board Meeting
  Re: Written Testimony by Community Access National Network on Enbrel review
• 02/16/24 - Colorado Prescription Drug Affordability Board Meeting
  Re: Written Testimony by Community Access National Network on Genvoya review
• 09/20/23 - Colorado Organizations and Individuals Responding to HIV/AIDS
  Re: Drug Board Must Prioritize Patient Access When Shaping Policies to Lower Drug Prices
• 09/15/23 - Colorado Prescription Drug Affordability Board Meeting
  Re: Written Testimony by Community Access National Network on Genvoya review

Opinions:

• 09/02/23 - Op-Ed by Jen Laws, President & CEO, Community Access National Network
  Re: Upper-payment limits; Drug "affordability" boards risk medication access

↩ Back to Prescription Drug Advisory Board Response Project Page